Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

1.

Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.

Tebas P, Spitsin S, Barrett JS, Tuluc F, Elci O, Korelitz JJ, Wagner W, Winters A, Kim D, Catalano R, Evans DL, Douglas SD.

AIDS. 2015 May 15;29(8):931-9. doi: 10.1097/QAD.0000000000000638.

PMID:
25915168
2.

Challenges and considerations for development of therapeutic proteins in pediatric patients.

Zhang Y, Wei X, Bajaj G, Barrett JS, Meibohm B, Joshi A, Gupta M.

J Clin Pharmacol. 2015 Mar;55 Suppl 3:S103-15. doi: 10.1002/jcph.382.

PMID:
25707958
3.

Malabsorption blood test: Assessing fat absorption in patients with cystic fibrosis and pancreatic insufficiency.

Mascarenhas MR, Mondick J, Barrett JS, Wilson M, Stallings VA, Schall JI.

J Clin Pharmacol. 2015 Feb 16. doi: 10.1002/jcph.484. [Epub ahead of print]

PMID:
25689042
4.

Adjuvant therapies for HIV-associated neurocognitive disorders.

McGuire JL, Barrett JS, Vezina HE, Spitsin S, Douglas SD.

Ann Clin Transl Neurol. 2014 Nov;1(11):938-52. doi: 10.1002/acn3.131. Epub 2014 Oct 23. Review.

5.

Novel method to predict body weight in children based on age and morphological facial features.

Huang Z, Barrett JS, Barrett K, Barrett R, Ng CM.

J Clin Pharmacol. 2015 Apr;55(4):447-51. doi: 10.1002/jcph.422. Epub 2015 Jan 6.

PMID:
25370186
6.

Predictors of arterial blood pressure control during deliberate hypotension with sodium nitroprusside in children.

Spielberg DR, Barrett JS, Hammer GB, Drover DR, Reece T, Cohane CA, Schulman SR.

Anesth Analg. 2014 Oct;119(4):867-74. doi: 10.1213/ANE.0000000000000376.

PMID:
25099924
7.

Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant.

Barrett JS, Bajaj G, McGuire J, Wu D, Spitsin S, Moorthy G, Zhao X, Tebas P, Evans DL, Douglas SD.

Curr HIV Res. 2014;12(2):121-31.

PMID:
24862330
8.

Fermentable oligosaccharides, disaccharides, monosaccharides and polyols: role in irritable bowel syndrome.

Tuck CJ, Muir JG, Barrett JS, Gibson PR.

Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):819-34. doi: 10.1586/17474124.2014.917956. Epub 2014 May 15.

PMID:
24830318
9.

Measurement of the survival probabilities for hot fusion reactions.

Yanez R, Loveland W, Yao L, Barrett JS, Zhu S, Back BB, Khoo TL, Alcorta M, Albers M.

Phys Rev Lett. 2014 Apr 18;112(15):152702. Epub 2014 Apr 17.

PMID:
24785034
10.

ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis.

Zuo XC, Zhang WL, Yuan H, Barrett JS, Hua Y, Huang ZJ, Zhou HH, Pei Q, Guo CX, Wang JL, Yang GP.

Drug Metab Pharmacokinet. 2014;29(4):305-11. Epub 2014 Feb 11.

11.

The grand challenges in obstetric and pediatric pharmacology.

Zajicek A, Barrett JS.

Front Pharmacol. 2013 Dec 30;4:170. doi: 10.3389/fphar.2013.00170. eCollection 2013. No abstract available.

12.

Response to Comment on low FODMAP diet.

Barrett JS, Gibson P.

Nutr Clin Pract. 2013 Dec;28(6):775-6. doi: 10.1177/0884533613503555. No abstract available.

PMID:
24264391
13.

Paediatric models in motion: requirements for model-based decision support at the bedside.

Barrett JS.

Br J Clin Pharmacol. 2015 Jan;79(1):85-96. doi: 10.1111/bcp.12287.

PMID:
24251868
14.

Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.

McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH.

Clin Cancer Res. 2014 Feb 1;20(3):754-63. doi: 10.1158/1078-0432.CCR-13-1960. Epub 2013 Nov 11.

15.

Functional bowel symptoms and diet.

Gibson PR, Barrett JS, Muir JG.

Intern Med J. 2013 Oct;43(10):1067-74. doi: 10.1111/imj.12266. Review.

PMID:
24134168
16.

Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children.

Jiang XL, Zhao P, Barrett JS, Lesko LJ, Schmidt S.

CPT Pharmacometrics Syst Pharmacol. 2013 Oct 16;2:e80. doi: 10.1038/psp.2013.55.

17.

PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions?

Barrett JS, McGuire J, Vezina H, Spitsin S, Douglas SD.

J Clin Psychopharmacol. 2013 Dec;33(6):725-8. doi: 10.1097/JCP.0b013e3182a88654.

PMID:
24100788
18.

Dietary sorbitol and mannitol: food content and distinct absorption patterns between healthy individuals and patients with irritable bowel syndrome.

Yao CK, Tan HL, van Langenberg DR, Barrett JS, Rose R, Liels K, Gibson PR, Muir JG.

J Hum Nutr Diet. 2014 Apr;27 Suppl 2:263-75. doi: 10.1111/jhn.12144. Epub 2013 Aug 3.

PMID:
23909813
19.

A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms.

Zajicek A, Fossler MJ, Barrett JS, Worthington JH, Ternik R, Charkoftaki G, Lum S, Breitkreutz J, Baltezor M, Macheras P, Khan M, Agharkar S, MacLaren DD.

AAPS J. 2013 Oct;15(4):1072-81. doi: 10.1208/s12248-013-9511-5. Epub 2013 Aug 2. Review.

20.

Letter: oral fructose--breath hydrogen response, symptoms, both or neither?

Barrett JS, Ng PS, Muir JG, Gibson PR.

Aliment Pharmacol Ther. 2013 Aug;38(4):442-3. doi: 10.1111/apt.12392. No abstract available.

PMID:
23855397
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk